[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590331":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":117,"collaborators":19,"id":119,"slug":120,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":19,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":127,"maxAge":19,"enrollmentInfo":128,"targetDuration":19,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},{"fullName":5,"class":6},"Deciphera Pharmaceuticals, LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DCC-2812","EXPERIMENTAL","Participants will receive DCC-2812 in dose escalation manner per dosing regimen depending upon evolving pharmacokinetic (PK), pharmacodynamic, and safety data.",[13],"Drug: DCC-2812",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered orally",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Clinical Team","STUDY_DIRECTOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","888-724-3274","clinicaltrials@deciphera.com",[30,51,67,84,101],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Dana-Farber Cancer Institute","RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-71.05977,42.35843,{"lat":42,"lon":41},[45,49],{"name":46,"role":26,"phone":47,"phoneExt":19,"email":48},"Bicky Thapa, MD","617-632-3000","bicky_thapa@dfci.harvard.edu",{"name":46,"role":50,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"facility":52,"status":32,"city":53,"state":54,"zip":55,"country":36,"countryCode":37,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"University of Michigan","Ann Arbor","Michigan","48109",{"type":39,"coordinates":57},[58,59],-83.74088,42.27756,{"lat":59,"lon":58},[62,65],{"name":19,"role":26,"phone":63,"phoneExt":19,"email":64},"800-865-1125","CancerAnswerLine@med.umich.edu",{"name":66,"role":50,"phone":19,"phoneExt":19,"email":19},"Ulka Vaishampayan, MD",{"facility":68,"status":32,"city":69,"state":70,"zip":71,"country":36,"countryCode":37,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Vanderbilt- Ingram Cancer Center","Nashville","Tennessee","37232",{"type":39,"coordinates":73},[74,75],-86.78444,36.16589,{"lat":75,"lon":74},[78,82],{"name":79,"role":26,"phone":80,"phoneExt":19,"email":81},"Vanderbilt- Ingram Cancer Center Clinical Trials Office (CTO)","1-800-811-8480","CTIP@VUMC.ORG",{"name":83,"role":50,"phone":19,"phoneExt":19,"email":19},"Brian Rini, MD",{"facility":85,"status":32,"city":86,"state":87,"zip":88,"country":36,"countryCode":37,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"NEXT Oncology, Austin","Austin","Texas","78758",{"type":39,"coordinates":90},[91,92],-97.74306,30.26715,{"lat":92,"lon":91},[95,99],{"name":96,"role":26,"phone":97,"phoneExt":19,"email":98},"Clinical Trial Navigator","737-610-5180","hwatson@nextoncology.com",{"name":100,"role":50,"phone":19,"phoneExt":19,"email":19},"Andrae Vandross, MD",{"facility":102,"status":32,"city":103,"state":87,"zip":104,"country":36,"countryCode":37,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"NEXT Oncology, San Antonio","San Antonio","78229",{"type":39,"coordinates":106},[107,108],-98.49363,29.42412,{"lat":108,"lon":107},[111,115],{"name":112,"role":26,"phone":113,"phoneExt":19,"email":114},"Jordan Georg","210-580-9521","jgeorg@nextoncology.com",{"name":116,"role":50,"phone":19,"phoneExt":19,"email":19},"Ildefonso Rodriguez Rivera, MD",{"type":118,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100590331","phase-1-study-of-dcc-2812-in-participants-with-advanced-genitourinary-cancers-100590331",false,"NCT06966024","Study of DCC-2812 in Participants With Advanced Genitourinary Cancers","An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer","Key Inclusion Criteria:\n\n* Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer\n* Able to take oral medication\n* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements\n* Adequate organ function and electrolytes\n\nKey Exclusion Criteria:\n\n* Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812\n* Impaired cardiac function\n* Major surgery within 28 days of the first dose of study drug","ALL","18 Years",{"count":129,"type":130},60,"ESTIMATED","INTERVENTIONAL",[133],"PHASE1","This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced\u002Fmetastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.",[136,137,138],"Renal Cell Carcinoma","Urothelial Carcinoma","Castration-resistant Prostate Cancer",[140],"Advanced malignancies","2026-05-18",{"date":143,"type":144},"2026-05-20","ACTUAL",{"date":146,"type":144},"2025-08-27",{"date":148,"type":130},"2029-02",{"name":5,"class":6},5]